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ABSTRACT 
 
Pakistanis belong to the South Asian population which has the highest known rate of coronary artery disease. 
Folic acid deficiency also appears to be highly prevalent in this population. Methylenetetrahydrofolate reduc-
tase (MTHFR) 677C>T polymorphism decreases the activity  of this enzyme and can be associated with mild to 
moderate hyperhomocysteinemia in homozygotes, particularly when there is folic acid deficiency, as well as 
with coronary artery disease. To assess the value of genotyping the MTHFR 677C>T dimorphism, we carried 
out  a  case-control  study  of  dimorphism  677C>T  for  putative  association  with  myocardial  infarction  (MI) 
among Pakistani nationals.  We investigated a sample population of 622 Pakistanis consisting of 225 controls 
and 397 patients with clinical diagnosis of acute MI (AMI). MTHFR C677T alleles were determined by assays 
based on polymerase chain reaction and restriction endonuclease analysis. Frequencies of C alleles were 0.87 
among controls and 0.86 among AMI patients.  The MTHFR 677C>T dimorphism showed no association with 
MI (χ
2 = 0.25, 1df, P=0.62), serum levels of folate and vitamin B12 and plasma level of vitamin B6.  A signifi-
cant association, however, was found between homozygous 677T genotype and plasma levels of homocysteine.  
Multivariate analysis of the data showed that in case of log homocysteine, age and MTHFR genotypes were 
significantly different (P<0.001).  In case of B12, smoking and age were found to be statistically significant 
(P<0.001), while in case of serum folate only smoking was found to be significant (P<0.001). The results indi-
cate that MTHFR 677C>T polymorphism, though associated with homocysteine levels, confers no significant 
risk of coronary artery disease in the Pakistani population investigated here. We suggest that the higher inci-
dence of AMI in South Asia occurs through mechanisms other than the MTHFR related pathways. 
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INTRODUCTION 
 
Pakistani  people  belong  to  a  population  which  has  the 
highest  rate  of  coronary  artery  disease  (CAD;  Nishtar, 
2002).  Moreover, the relative risk of CAD in South Asian 
men is highest at early ages (Balarajan, 1991; McKeigue, 
1992) suggesting that both intrinsic and extrinsic factors 
contribute to the development of CAD in this population.  
 
Methylenetetrahydrofolate  reductase  (MTHFR)  catalyzes 
the  reduction  of  5,  10-methylenetetrahydrofolate  to  5-
methyltetrahydrofolate, a carbon donor in the methylation 
of homocysteine to methionine.  A C677T mutation in the 
MTHFR gene (MTHFR) converts an alanine residue to a 
valine residue and functionally impairs the enzyme (Frosst 
et al, 1995). The aberration leads to hyperhomocysteine-
mia, an independent risk factor for cardiovascular disease 
(Aguilar et al, 2004). 
 
Although numerous reports have brought somewhat con-
flicting views about the involvement of MTHFR in CAD, 
it is now commonly accepted that the MTHFR gene and its   
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molecular variant 677C>T represent one of the best exam-
ples to date of genetic influences that constitute inherited 
predispositions to CAD and allied clinical manifestations 
in humans (Kluijtmans, 1996). Association (case-control) 
studies are increasingly  preferred as  methods for under-
standing genetic influences of molecular variants (Lander, 
1996; Risch and Merikangas, 1996). Data from genetically 
isolated  populations  are  important  in  the  resolution  of 
problems related to the concept of linkage disequilibrium 
(Schork, 1997). 
 
Chambers et al (2000) pointed out that Indian Asians re-
siding in the United Kingdom have twice the rate of coro-
nary heart disease  deaths compared to European Cauca-
sians, and hyperhomocysteinemia in this population could 
be a contributing factor.  However, MTHFR 677T muta-
tion was not found to be associated with hyperhomocys-
teinemia or increased CAD risk in Indian Asians compared 
to Europeans (Chambers et al., 2000).  In a similar case-
control study on Indians by Mukharjee et al (2002) a low 
prevalence  of  MTHFR  677T  mutation  was  observed  in 
both normal healthy subjects and CAD patients, however, 
an association of the mutant allele with CAD was found in 
women. 
 
While mild hyperhomocysteinemia has been reported to be 
quite  common  among  South  Asians  including  the  Paki-
stanis (Sastry et al, 2001; Aamir et al, 2004; Iqbal et al, 
2005),  the role of MTHFR mutation in causing this hyper-
homocysteinemia is still unclear. 
 
Since folate, vitamin B6 and vitamin B12 deficiencies are 
very common in Pakistani patients with acute myocardial 
infarction (AMI; Iqbal et al, 2005), the role of MTHFR 
mutations could be of more significance in causing hyper-
homocysteinemia, and thereby, increasing the risk for the 
development of CAD. 
 
The present study was undertaken to assess the usefulness 
of MTHFR marker 677C>T in the Pakistani population as 
an independent risk factor for CAD in Pakistanis.  A case-
control study of dimorphism 677C>T was carried out for a 
putative  association  with  AMI  (a  presentation  of  CAD) 
and with plasma or serum levels of homocysteine, folate, 
vitamin B12 and vitamin B6 (pyridoxal phosphate, PLP) 
amongst Pakistani nationals. 
 
MATERIALS AND METHODS 
 
Patients and methods 
Three  hundred  and  ninety  seven  consecutive  Pakistani 
patients with AMI (age range: 30-74 years) admitted to the 
National  Institute  of  Cardiovascular  Diseases  (NICVD), 
Karachi from January 2001 to June 2001, and the Armed 
Forces  Institute  of  Cardiology,  Rawalpindi  from  August 
2003  to  September  2003,  were  included  in  this  study.  
They were enrolled within the index admission after con-
firmation  of  AMI  diagnosis  based  on  WHO  criteria  of 
clinical history suggestive of myocardial ischaemia, ECG 
indications of myocardial damage, and elevation of bio-
chemical  markers  (creatine  kinase  and  creatine  kinase-
MB).  All patients were assessed as having risk factors for 
CAD,  such  as  diabetes  mellitus,  hypertension,  obesity, 
hypercholesterolemia and smoking.  Criteria for diabetes 
were set as an abnormal fasting blood glucose level > 125 
mg/dl at admission, or having taken hypoglycemic agents.  
All  those  with  systolic  blood  pressure  greater  than  140 
mmHg  and/or  diastolic  blood  pressure  of  90  mmHg  or 
those on regular antihypertensive medications were classi-
fied as hypertensive. Those with serum cholesterol levels 
greater than 200 mg/dl were considered to have hypercho-
lesterolemia. A body mass index (BMI) of greater than 30 
was classified as obese.  Subjects were considered smok-
ers if they had been smoking cigarettes regularly (one or 
more per day).  Individuals who were pregnant, using an-
tiepileptics, taking oral contraceptives, having malabsorp-
tion syndrome, suffering from tuberculosis, liver disease, 
uremia,  or  cancer  or  using  vitamin  B-complex  supple-
ments during the previous 6 months were excluded from 
the study. 
 
Similarly,  225  normal  healthy  subjects,  who  had  been 
matched for sex, BMI, and for age within 5 years and be-
longing to the same socio-economic class, were selected as 
controls during the same period from the personnel of the 
Aga  Khan  University  and  Civil  Hospital,  Karachi,  and 
Armed Forces Institute of Cardiology and Military Hospi-
tal, Rawalpindi.  They were also assessed for the above 
mentioned risk factors.  However, more stringent criteria 
were used for the selection of normal healthy control sub-
jects. In addition to being matched for BMI, sex, age and 
socioeconomic background, they had no evidence of CAD 
and hypertension on the basis of their clinical history and 
physical  examination.    Informed  consent  was  obtained 
from the participants and the study was approved by the 
Ethical Review Committee of the Aga Khan University. 
 
DNA analysis   
DNA was extracted from 5 ml blood samples according 
to published methods (Sambrook et al, 1989). C677T of 
the  MTHFR  gene  was  amplified  by  polymerase  chain 
reaction  (PCR)  according  to  protocol  conditions  and 
primer  sequences  published  previously  (Frosst  et  al, 
1995), except that PCR volumes were scaled down to 10 
µl.  A  Perkin-Elmer  Gene  Amp  PCR  system  9700  was 
utilized  (Wellesley,  MA,  USA).  C677T  PCR  products 
were  digested  with  HinfI  (New  England  Biolabs,  Bev-
erly, MA) at 37ºC for 3 hr, size-separated by gel electro-
phoresis using 2% (w/v) agarose at 150 volts for 1 hr, 
and  visualized  under  UV  light  after  staining  with 
ethidium bromide. 677C alleles were identified as  198  
base pairs (bp) fragments and 677T alleles as 175 and 23 
bp fragments (Frosst et al, 1995). 
 
Estimation of vitamin B12, folate, B6 and homocysteine 
in serum/plasma 
Fasting venous blood was obtained from cases as well as 
controls. Serum samples were analyzed for folate and vi-
tamin  B12  using  radioassays  (Chanarin,  1989;  Quadros, 
2000). Plasma samples from both cases and controls were 
screened for pyridoxal phosphate (PLP; coenzymic form 
of  vitamin  B6) and  homocysteine.   PLP in  plasma  was 
determined using a method described previously (Iqbal, et 
al, 2003). Determination of plasma homocysteine was car-
ried  out  using  a  kit  based  on  fluorescence  polarization 
immunoassay (Abbott Laboratories, Ltd., Pakistan).  
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Data analysis   
Statistical analyses were done with the help of an SPSS® 
(Statistical Package for Social Sciences) software version 
13.0 for Windows
® Apache Software Foundation, USA). 
Distribution  differences  of  MTHFR  genotypes  in  AMI 
patients  as  compared  to  controls,  as  well  as  Hardy-
Weinberg proportions of allele distribution, were assessed 
using  chi-square  test.  Homocysteine  values  were  con-
verted to logs, as the data were not normally distributed.  
Means were compared using one way analysis of variance 
(ANOVA). Significant differences were identified using a 
Post-Hoc test (Dunnett T3) for MTHFR genotypes, when 
homogeneity of variance was found to be significant. 
 
Multivariate analysis was performed using values for log 
homocysteine, vitamin B12, vitamin B6 and folate as out-
come  variables,  whereas  cases  and  controls,  MTHFR 
genotypes, age and smoking status were independent vari-
ables.  A p-value less than 0.05 was considered significant. 
 
RESULTS 
 
Table 1 shows the demographic and clinical characteristics 
of patients and normal healthy control subjects.  Patient 
and control groups had female to male ratios of about 1:3.  
The mean age was slightly higher for patients.  Mean BMI 
values for the two groups were similar. 
 
Table 2 shows the distributions of 677C and 677T alleles, 
as well as those of genotypes of MTHFR 677C>T dimor-
phism in AMI patients and controls.  Frequencies of the 
677T  alleles  were  0.13  in  controls  and  0.14  in  cases.  
MTHFR  genotypes  were  found  to  occur  in  Hardy-
Weinberg proportions in the normal as well as the patient 
groups (P=0.53 and P=0.45 with 2 df, respectively). 
 
We also explored association of MTHFR genotypes with 
several phenotypic variables, including plasma homocys-
teine, serum folate, serum B12 and plasma PLP (Table 
3).  While  studying  the  association  between  MTHFR 
genotypes and homocysteine, log transformation of ho-
mocysteine revealed that homocysteine value in the TT 
group was significantly different from that of both CC 
(P<0.03) and CT groups (P<0.004) for both patients and 
controls.  However, between cases and controls, differ-
ences were not found to be statistically significant.  In 
multivariate analysis, log homocysteine, B12 and folate 
were found to be significant.  With regard to log homo-
cysteine, age and MTHFR  genotypes were found to be 
significantly  different  (P<0.001).    With  B12,  smoking 
and  age  were  found  to  be  statistically  significant 
(P<0.001), whereas for serum folate, only smoking was 
found to be significant (P<0.001). 
 
DISCUSSION 
 
Normal healthy subjects included in this study constituted 
a  “comparison”  group, rather than  a  true  control  group.  
Since they had no evidence of CAD on the basis of their 
clinical history and were matched for sex, age and BMI, 
they represented a valid comparison group. However, it is 
likely that  some of them will develop CAD in future, and 
some might even have heart disease at a subclinical, i.e. 
undetectable level. 
 
 
 
Table 1.  Demographic and clinical characteristics of Pakistani subjects 
 
Controls 
(n=225) 
AMI Patients 
(n=397)   
Mean ± SD (Range)  Frequency (%)  Mean ± SD (Range)  Frequency (%) 
Age  (Years) 
 
49 ± 8.8 
(30-75) 
 
 
53.5 ± 10.1 
(30-74) 
 
Gender 
   (Male) 
   (Female) 
 
 
173 (76.9) 
52 (23.1) 
 
 
309 (77.8) 
88 (22.2) 
Body mass index* 
(kg/m
2) 
   
 >30 (obese) 
23.86 ± 5.3 
(13.48-45.28) 
 
 
 
 
 
19 (8.4) 
25.1 ± 3.9 
(10.77-43.75) 
 
 
 
 
 
43 (10.8) 
Smoking status* 
   (smokers) 
   (non-smokers) 
 
 
38 (17.2) 
183 (82.8) 
 
 
109 (28.6) 
272 (71.4) 
Hypertension* 
   (Yes) 
   (No) 
 
 
0 
225 (100) 
 
 
175 (44.9) 
215 (55.1) 
Diabetes* 
   (Yes) 
   (No) 
   Glucose (mg/dl) 
 
 
 
 
96 ± 27 
(51-230) 
6 (2.6) 
219 (97.4) 
 
 
 
 
137 ± 76 
(51-578) 
 
122 (31.4) 
267 (68.6) 
 
Hypercholesterolemia*  
   (Yes) 
Total-cholesterol (mg/dl) 
 
 
 
166 ± 35 
(61-230) 
13 (5.8) 
 
 
 
179 ± 49 
(68-457) 
70 (17.6) 
 
 
*As defined in the Patients and Methods section.  
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Table 2.  Distribution of MTHFR 677C>T genotypes and allele frequencies (Means± standard errors) in normal healthy subjects and 
AMI patients   
 
Normal healthy subjects 
(n=225) 
AMI patients 
(n=397) 
Odds Ratio (OR) 
(95% C.I.)  Genotype* 
n(%)  n(%)   
CC  161(71.6)  279(70.2) 
 
0.7 
(0.2-1.8) 
 
CT  57(25.3)  110(27.7) 
 
0.6 
(0.2-1.7) 
TT  7(3.1)  8(2.0)  1 
p(C allele)**  0.87 ± 0.02  0.86 ± 0.02   
 
q(T allele)**  0.13 ±  0.02  0.14 ± 0.02   
 
 
*χ
2=1.029; 2 df; P=0.598 
**χ
2=0.25; 1 df; P=0.62 
 
 
 
 
 
Table 3.  MTHFR genotypes, age and concentrations of plasma/serum homocysteine, folate, vitamin B12 and PLP in normal healthy 
subjects (controls) and AMI patients 
 
MTHFR Genotype  Subjects  
CC  CT  TT 
Controls 
  Age (years) 
 
49.7 ±  8.7 
 
48 ± 8.7 
 
40.9 ± 8.0 
 
  Fasting homocysteine  (µmol/l) 
  [Log transformed] 
 
2.79 ± 0.33 
 
2.86 ±0.36 
 
3.21 ± 0.65 
 
   Serum folate (ng/ml) 
 
4.62 ± 2.93 
 
5.01 ± 2.71 
 
2.89 ± 4.1 
 
   Serum B12 (pg/ml) 
 
547 ± 314 
 
517 ± 260 
 
384 ± 177 
 
   Plasma PLP (nmol/l) 
 
21.3 ± 15.7 
 
22.1 ± 12.2 
 
34 ± 30.6 
 
AMI Patients 
 
     
 
   Age (years) 
 
54 ± 10.2 
 
52.7 ± 9.7 
 
47.4 ± 10.6 
 
   Fasting homocysteine (µmol/l) 
   [Log transformed] 
2.83 ±0.38  2.83 ± 0.44  3.56 ± 0.42 
 
   Serum folate (ng/ml) 
 
3.9 ± 3.1 
 
3.8 ± 2.7 
 
2.3 ± 2.7 
 
   Serum B12 (pg/ml) 
 
250 ± 171 
 
276 ± 199 
 
226 ± 121 
 
   Plasma PLP (nmol/l) 
 
22.3 ± 24.8 
 
22.3 ± 19.9 
 
16 ± 11.8 
 
 
Pakistan is facing a huge challenge in combating CAD 
(Ahmad,  2002;  Bhopal,  2002).  According  to  the  most 
careful  estimates,  nearly  100,000  individuals  in  a  total 
population of about 150 million suffered AMI in Pakistan 
in  the  calendar  year  2002  (Samad,  2003).  This  rate  is 
alarmingly high.  High prevalence of folate, B12 and B6 
deficiencies  along  with  mild  hyperhomocysteinemia 
could be contributing to this high CAD rate (Iqbal et al, 
2005).  These observations pointed towards the possible 
role of MTHFR gene in the development of CAD in this 
population. 
 
Several studies have suggested that MTHFR 677C>T mu-
tation confers increased risk for CAD (Kluijtmans et al, 
1997).  At the same time, quite a few reports show no as-
sociation between this mutation and the risk of CAD, es-
pecially among Asians (Chambers et al, 2000, Wang et al, 
2001, Kim et al, 2001, Mukherjee et al, 2002).  In the pre-
sent  study,  we  report  that  the  allele  frequencies  of  the 
MTHFR 677C>T polymorphism in the Pakistani normal 
subjects are 0.87 ± 0.02 and 0.13 ± 0.02 for the 677C and 
677T alleles, respectively, while in AMI patients, these are 
0.86 ± 0.02 and 0.14 ± 0.02, respectively.  This low preva-
lence of mutant allele (T allele) among cases and controls 
in our study compares well with “T” allelic frequencies of 
0.18  and  0.19  in  normal  healthy  subjects  and  CAD  pa-
tients,  respectively,  in  a  population  of  Asian  Indians 
(Mukerjee et al, 2002). Similarly, the overall homozygous  
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MTHFR TT variant frequency of 0.024 in this study com-
pares  well  with  an  observed  frequency  of  0.02  among 
South Asians living in England (Cappuccio et al, 2002).  
Analysis of our data revealed that C677T genotype distri-
butions were in Hardy-Weinberg proportions, both in the 
control group and AMI patient group.   
 
Our data did not show any significant association be-
tween 677C>T polymorphism and AMI (a presentation 
of CAD) in the Pakistani population sampled.  Since the 
overall effect of MTHFR mutation 677C>T on CAD has 
been  postulated  to  occur  through  hyperhomocysteine-
mia, we  searched for  any association  between  plasma 
levels of homocysteine and MTHFR 677C>T polymor-
phism.  Many reports based on data from various popu-
lations show association of homozygous MTHFR 677T 
genotypes with raised plasma homocysteine concentra-
tions (Frosst et al, 1995; Ma et al, 1996; Kluijtmans et 
al, 1996; Kluijtmans et al, 1997; Verhoef et al, 1997; 
Brattstrom et al, 1998; Nair et al, 2002; Yilmaz et al, 
2005), especially in the presence of low folate (Jasques 
et  al,  1996;  Ma  et  al,  1996;  Christensen  et  al,  1997; 
Schwatz et al, 1997; Gemmati et al, 1999).  Our results 
are  quite  consistent  with  these  observations;  in  both 
AMI  patients  and  controls  (with  serum  folate  levels 
quite low compared to most Western populations), ho-
mozygous MTHFR 677T genotype was found to be as-
sociated with elevated concentrations of plasma homo-
cysteine (P<0.001).   
 
Since  total  serum  levels  of  homocysteine  have  been 
shown  to  depend  on  both  genetic  and  environmental 
factors, the role of folate status cannot be overlooked.  
Although  differences  in  serum  folate  in  the  present 
study  are  not  statistically  significant  between  geno-
types,  homozygous  mutant  individuals  (TT  genotype) 
do have lower serum folate in both controls and AMI 
patients (Table 3).   It is possible that the mutation itself 
may  affect  serum  folate  levels  because  5-
methyltetrahydrofolate is  the  primary circulating form 
of folate and in severe MTHFR deficiency, the propor-
tion  of  intracellular  folate  (5-methyltetrahydrofolate) 
has been shown to be reduced (Rosenblatt, 1995). 
 
Matsushita et al (1997) reported that frequencies of ho-
mozygous MTHFR genotypes 677T decrease with age in 
the  normal  population,  and  that  younger  people  (<  55 
years)  have  higher  frequency  of  homozygous  MTHFR 
mutation than older ones (> 55  years).  Chamber et al 
(2000) also reported a higher frequency of homozygosity 
for MTHFR 677T in cases with onset of coronary heart 
disease before the age of 50 years.  In the present study, a 
similar  nonsignificant  (P=0.25)  trend  was  observed  as 
homozygous MTHFR mutation (TT genotype) occurred 
in 1.5% of subjects over 50 compared to 3.5% in those 
below the age of 50.  Further studies involving a larger 
sample  size  would  be  required  to  ascertain  whether 
younger  subjects  have  significantly  high  prevalence  of 
TT genotype as it might account for the high risk of CAD 
in our younger population (Virk et al, 1995). 
 
Frequencies  of  MTHFR  677T  homozygotes  in  both 
cases and controls in our population were 2% and 3.1%, 
respectively (Table 2).  These values are quite compa-
rable with those reported by Chambers et al (2000) who 
have  found  these  frequencies  to  be  1%  (in  coronary 
heart  disease  patients)  and  3%  (in  normal  controls) 
among Indian Asians residing in the United Kingdom. 
Mukherjee et al. (2002) found these values to be 2% in 
normal  control  subjects,  and  zero  in  CAD  patients 
among  Asian Indians.   In contrast, the frequencies  of 
homozygous mutant gene in controls and cases in three 
US populations were in the range 10% - 13.1% (Ma et 
al, 1996; Schwartz et al, 1997; Anderson et al, 1997), 
10.5%  -  10.6%    in  Western  Australians  (Van  Bockx-
meer et al, 1997), 10% - 14% in Canadians (Christensen 
et al, 1997), 9% - 11%  in Poles (Goracy et al, 1999), 
12.3% - 12.8%  in Chinese  (Zheng  et  al, 2000), 5.8% 
and 12.1% in Slovakians (Raslova et al, 2001) and 10% 
- 14%  in European Caucasians  (Chambers et al, 2000), 
respectively. 
 
While  homozygosity  for  MTHFR  677T  is  associated 
with hyperhomocysteinemia in the Pakistani population, 
it  appears  not  to  be  an  important  determinant  of  in-
creased CAD mortality in this population. Mild hyper-
homocysteinemia,  perhaps  through  an  interplay  with 
other  cardiovascular  risk  factors,  such  as  smoking, 
dyslipidemia  (especially  low  HDL  cholesterol),  nutri-
tional  deficiencies  (folate,  B12  and  selenium),  and 
raised  fasting  glucose  could  be  enhancing  the  risk  of 
CAD in Pakistan. 
 
CONCLUSIONS 
 
• MTHFR  mutation  (677  C>T)  is  relatively  rare  among 
Pakistanis and the MTHFR TT genotype does not appear 
to be a risk factor for AMI in the population investigated.  
  
• We hypothesize that the higher AMI incidence in South 
Asia (especially in Pakistan) occurs through mechanisms 
other than the MTHFR related pathways. 
 
• Bearing in mind the complex nature of genetic suscepti-
bility  for chronic  degenerative diseases, further studies 
need to be conducted in individual ethnic groups (involv-
ing younger subjects) taking into account their nutritional 
status in terms of vitamins B6, B12 and folic acid to ver-
ify the disease relevance of this polymorphism. 
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LIST OF ABBREVIATIONS  
 
MI: Myocardial infarction 
AMI: Acute myocardial infarction 
CAD: Coronary artery disease 
BMI: Body mass index 
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